Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay

被引:137
作者
Maertens, Johan A.
Klont, Rocus
Masson, Christine
Theunissen, Koen
Meersseman, Wouter
Lagrou, Katrien
Heinen, Christine
Crepin, Brigitte
Van Eldere, Johan
Tabouret, Marc
Donnelly, J. Peter
Verweij, Paul E.
机构
[1] Catholic Univ Louvain, Dept Hematol, Univ Ziekenhuizen, B-3000 Louvain, Belgium
[2] Catholic Univ Louvain, Dept Intens Care Med, Univ Ziekenhuizen, B-3000 Louvain, Belgium
[3] Catholic Univ Louvain, Dept Med Microbiol, Univ Ziekenhuizen, B-3000 Louvain, Belgium
[4] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, Nijmegen, Netherlands
[5] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[6] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands
[7] BioRad Labs, Marnes La Coquette, France
[8] BioRad Labs, Steenvoorde, France
关键词
D O I
10.1086/514349
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Many health care centers worldwide use the Platelia Aspergillus enzyme immunoassay (PA-EIA; Bio-Rad Laboratories) for diagnosis of invasive aspergillosis (IA). A cutoff optical density (OD) index of 1.5 was originally recommended by the manufacturer, but in practice, most institutions use lower cutoff values. Moreover, a cutoff OD index of 0.5 was recently approved in the United States. In the present study, we set out to optimize the cutoff level by performing a retrospective analysis of PA-EIA values for samples that had been obtained prospectively from adult patients at risk for IA at 2 European health care centers. Methods. In total, 239 treatment episodes were included of which there were 19 episodes of proven IA and 19 episodes of probable IA. Per-episode and per-test analyses and receiver operating characteristic curves were used to determine the optimal cutoff value. Results. In the per-episode analysis, lowering the cutoff OD index for positivity from 1.5 to 0.5 increased the overall sensitivity by 21% (from 76.3% to 97.4%) but decreased the overall specificity by 7% ( from 97.5% to 90.5%). Requiring 2 consecutive samples with an OD index >= 0.5 resulted in the highest test accuracy, with an improved positive predictive value. At a cutoff OD index of 0.5, the antigen test result was positive during the week before conventional diagnosis in 65% of cases and during the week of diagnosis in 79.5% of cases. Conclusions. A cutoff OD index of 0.5 - identical to the approved cutoff in the United States - improves the overall performance of the PA-EIA for adult hematology patients.
引用
收藏
页码:1329 / 1336
页数:8
相关论文
共 34 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]   Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with β-lactam antibiotics in patients with hematological disorders [J].
Aubry, A ;
Porcher, R ;
Bottero, J ;
Touratier, S ;
Leblanc, T ;
Brethon, B ;
Rousselot, P ;
Raffoux, E ;
Menotti, J ;
Derouin, F ;
Ribaud, P ;
Sulahian, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (02) :389-394
[3]   Serum Aspergillus galactomannan antigen testing by sandwich ELISA: Practical use in neutropenic patients [J].
Bretagne, S ;
MarmoratKhuong, A ;
Kuentz, M ;
Latge, JP ;
BartDelabesse, E ;
Cordonnier, C .
JOURNAL OF INFECTION, 1997, 35 (01) :7-15
[4]   Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning [J].
Fukuda, T ;
Boeckh, M ;
Carter, RA ;
Sandmaier, BM ;
Maris, MB ;
Maloney, DG ;
Martin, PJ ;
Storb, RF ;
Marr, KA .
BLOOD, 2003, 102 (03) :827-833
[5]   Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients [J].
Herbrecht, R ;
Letscher-Bru, V ;
Oprea, C ;
Lioure, B ;
Waller, J ;
Campos, F ;
Villard, O ;
Liu, KL ;
Natarajan-Amé, S ;
Lutz, P ;
Dufour, P ;
Bergerat, JP ;
Candolfi, E .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1898-1906
[6]   Laboratory diagnosis of invasive aspergillosis [J].
Hope, WW ;
Walsh, TJ ;
Denning, DW .
LANCET INFECTIOUS DISEASES, 2005, 5 (10) :609-622
[7]   Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients [J].
Kuderer, NM ;
Dale, DC ;
Crawford, J ;
Cosler, LE ;
Lyman, GH .
CANCER, 2006, 106 (10) :2258-2266
[8]   False-positive Aspergillus galactomannan antigen test results [J].
Maertens, J ;
Theunissen, K ;
Verhoef, G ;
Van Eldere, J .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) :289-290
[9]   Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients [J].
Maertens, J ;
Theunissen, K ;
Verbeken, E ;
Lagrou, K ;
Verhaegen, J ;
Boogaerts, M ;
Van Eldere, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (06) :852-860
[10]   Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation [J].
Maertens, J ;
Verhaegen, J ;
Lagrou, K ;
Van Eldere, J ;
Boogaerts, M .
BLOOD, 2001, 97 (06) :1604-1610